Atlas Trials

Safety of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells in Adult Patients With Diffuse Large B-cell Lymphoma

Clinical trial NCT04215016 · UNKNOWN

Trial details

NCT number
NCT04215016
Sponsor
Fujian Medical University
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Relapsed or Refractory DLBCL Patients With Either CD19 or CD20 Positive
Start date
2019-12-01
Primary completion
2023-12-01
Enrollment
18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.